AegirBio AB (publ) announced that it will issue units for the gorss proceeds of SEK 55 million in a round of funding on December 20, 2022. each unit will consist of 1 Convertible Bond, 2517 Warrant Of Series TO3, 2183 Warrants Of Series TO4. The transaction will include participation from Atlas Special Opportunities LLC., Atlas Special Opportunities LLC, shall pay cash consideration of SEK 48,950,000, corresponding to 89 percent of total nominal amount of convertible bonds.

Convertible bonds run with zero interest and are due for payment 24 months from date when extraordinary general meeting decides on unit issue, remaining 11 percent of total nominal amount of convertible bonds is paid by Atlas Special Opportunities LLC by way of set-off against fees to be paid by the company.